High-Dose Inhaled Steroids And Increased Risk Of Glaucoma

10 March 1997

- Prolonged use of high doses of inhaled steroids have been linked to anincreased risk of developing glaucoma in later life, according to a report in the Journal of the American Medical Association (March 5). No increased risk was associated with continuous use of low- and medium-dose inhaled steroids, according to the report. Shares in asthma companies, including Glaxo Wellcome, dropped slightly on the news. However, GW dismissed the JAMA report as purely an epidemiological meta-analysis and said it had no data to support the findings. Nor did GW think this would have any impact on sales of its inhaled steroids.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight